“We will continue to focus on high-value targets in biopharma”

Hummingbird Bioscience, an innovative clinical-stage biotech company with its APAC headquarter in Singapore, with 60 employees is focused on developing precision therapies against hard-to-drug targets via a unique data-driven systems biology approach.

- Hithaishi C Bhaskar

Dr Piers Ingram, Co-founder & CEO, Hummingbird Bioscience, Singapore

On May 18, 2021, it announced the closure of its $125 million Series C financing round. The investment strengthens its competence to solve complex challenges in antibody development to deliver highly differentiated therapies. Proceeds will essentially support the advancement of its lead assets in clinical trials and the building of its next-generation portfolio of precision biotherapeutics. Speaking with BioSpectrum Asia, Dr. Piers Ingram, Co-founder & CEO at Hummingbird Bioscience, Singapore provides additional insights on investment and the company’s accelerated clinical development activities. Edited excerpts;

How essential is the progress of precision therapies and hard-to-drug targets in the APAC drug development sector?